Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration has approved updated COVID-19 vaccines from ... “We are still awaiting more information from the FDA, including when the current 2023-2024 vaccine will be ...
U.S. regulators approved updated COVID-19 vaccines on Thursday, shots designed to more closely target recent virus strains -- and hopefully whatever variants cause trouble this winter, too.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
The test, which on Wednesday received emergency-use authorization from the U.S. Food and Drug Administration (FDA), measures the number of neutralizing antibodies that the body’s immune system ...
A third U.S. manufacturer, Novavax, expects its modified vaccine version to be available a little later. "We strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants,” said FDA vaccine chief Dr. Peter Marks.
An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a ...
Earlier this month, the health regulator approved updated COVID-19 vaccines made by Pfizer and Moderna targeting the KP.2 variant. JN.1 was the dominant strain in the United States earlier this year.
[86] In the US, newly inaugurated US president Joe Biden released a national strategy for COVID-19 that pledged to "fund rapid test acquisition and distribution for priority populations, work to spur development and manufacturing of at-home tests and work to ensure that tests are widely available." [87] In March 2021, the US FDA authorized the ...